Antigen‐specific suppression of established arthritis in mice by dendritic cells deficient in NF‐κB
Open Access
- 28 June 2007
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (7) , 2255-2266
Abstract
Objective: NF‐κB inhibitors applied to animal models of rheumatoid arthritis (RA) demonstrate the important role of NF‐κB in the production of mediators of inflammation in the joint and their antiinflammatory effects. Because NF‐κB is involved in the differentiation, activation, and survival of almost all cells, its prolonged inhibition might have unwanted adverse effects. Therefore, we sought to apply NF‐κB inhibitors more specifically, targeting dendritic cell (DC) differentiation, in order to influence the outcome of the autoimmune response, rather than to produce a broad antiinflammatory effect. We tested whether DCs treated with the NF‐κB inhibitor BAY 11‐7082 and exposed to arthritogenic antigen would suppress established arthritis in C57BL/6 mice.Methods: Antigen‐induced arthritis was generated in C57BL/6 mice by injection of methylated bovine serum albumin (mBSA). After mBSA challenge, mouse knee joints were injected with antigen‐exposed BAY 11‐7082–treated DCs or with soluble tumor necrosis factor receptor (sTNFR). Intraarticular injection of interleukin‐1 (IL‐1) was used to induce disease flare.Results: Inflammation and erosion were suppressed in mice that received mBSA‐exposed BAY 11‐7082–treated DCs, but not in those that received keyhole limpet hemocyanin–exposed BAY 11‐7082–treated DCs. Clinical improvement was dependent on IL‐10 and was associated with antigen‐specific suppression of the delayed‐type hypersensitivity (DTH) reaction and switching of anti‐mBSA antibody isotype from IgG2b to IgG1 and IgA. Suppression of the DTH reaction or arthritic disease was not impaired by concomitant administration of sTNFR. Suppression could be reversed with intraarticular administration of IL‐1β and could be restored by a second injection of mBSA‐exposed BAY 11‐7082–treated DCs.Conclusion: BAY 11‐7082–treated DCs induce antigen‐specific immune suppression in this model of inflammatory arthritis, even after full clinical expression of the disease. Such DCs have potential as antigen‐specific therapy for autoimmune inflammatory arthritis, including RA.Keywords
This publication has 49 references indexed in Scilit:
- Myeloid suppressor cells regulate the adaptive immune response to cancerJournal of Clinical Investigation, 2006
- A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullinationArthritis & Rheumatism, 2005
- Antigen‐specific immunomodulation of collagen‐induced arthritis with tumor necrosis factor–stimulated dendritic cellsArthritis & Rheumatism, 2004
- CD4+CD25+ TR Cells Suppress Innate Immune Pathology Through Cytokine-dependent MechanismsJournal of Experimental Medicine, 2003
- Repetitive Injections of Dendritic Cells Matured with Tumor Necrosis Factor α Induce Antigen-specific Protection of Mice from AutoimmunityJournal of Experimental Medicine, 2001
- Leflunomide: mode of action in the treatment of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2000
- Novel Inhibitors of Cytokine-induced IκBα Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in VivoJournal of Biological Chemistry, 1997
- Nuclear factor–kB in rheumatoid synovium. Localization of P50 and P65Arthritis & Rheumatism, 1995
- Suppression of Collagen Induced Arthritis by Oral Administration of Type II Collagen: Changes in Immune and Arthritic Responses Mediated by Active Peripheral SuppressionAutoimmunity, 1993
- Flare-up of experimental arthritis in mice with murine recombinant IL-1Clinical and Experimental Immunology, 1992